Literature DB >> 9332517

Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes.

A C White1, R L Atmar, J Wilson, T R Cate, C E Stager, S B Greenberg.   

Abstract

Antimicrobial control programs are widely used to decrease drug expenditures, but effects on antimicrobial resistance and outcomes for patients are unknown. When a requirement for prior authorization for selected parenteral antimicrobial agents was initiated at our urban, county teaching hospital, total parenteral antimicrobial expenditures decreased by 32%. Susceptibilities to all beta-lactam and quinolone antibiotics increased, with dramatic increased susceptibilities in isolates recovered in intensive care units, increased susceptibilities in isolates recovered in other inpatient sites, and little change in susceptibilities in isolates recovered in outpatient sites despite no change in infection control practices. For patients with bacteremia due to gram-negative organisms, overall survival did not change with restrictions. No differences occurred in the median time from initial positive blood culture to receipt of an appropriate antibiotic or in the median time from positive blood culture to discharge from the hospital. Thus, requiring preapproval for selected parenteral agents can decrease antimicrobial expenditures and improve susceptibilities to antibiotics without compromising patient outcomes or length of hospital stay.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332517     DOI: 10.1086/514545

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  57 in total

1.  Fluorescent In situ hybridization allows rapid identification of microorganisms in blood cultures.

Authors:  V A Kempf; K Trebesius; I B Autenrieth
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions.

Authors:  Elaine S Walker; Foster Levy; Mahmoud Shorman; Gerard David; Jehad Abdalla; Felix A Sarubbi
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

3.  Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals.

Authors:  Carl T Bergstrom; Monique Lo; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-12       Impact factor: 11.205

4.  Antimicrobial stewardship.

Authors:  Shira Doron; Lisa E Davidson
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

5.  Reserve drug indent form and its impact on antimicrobial consumption and sensitivity pattern in the medical intensive care unit of a tertiary care hospital.

Authors:  Deepthi P Shridhar; K B Anitha; Mohandas Rai; Anisha Fernandes
Journal:  J Clin Diagn Res       Date:  2015-02-01

Review 6.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 7.  Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.

Authors:  Jaume Puig-Junoy; Iván Moreno-Torres
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  Optimization of antibiotic use in hospitals--antimicrobial stewardship and the EU project ABS international.

Authors:  Franz Allerberger; Arno Lechner; Agnes Wechsler-Fördös; Roland Gareis
Journal:  Chemotherapy       Date:  2008-07-31       Impact factor: 2.544

9.  Effect of communication errors during calls to an antimicrobial stewardship program.

Authors:  Darren R Linkin; Neil O Fishman; J Richard Landis; Todd D Barton; Steven Gluckman; Jay Kostman; Joshua P Metlay
Journal:  Infect Control Hosp Epidemiol       Date:  2007-11-01       Impact factor: 3.254

10.  Antimicrobial stewardship - can we afford to do without it?

Authors:  Anna Aryee; Nicholas Price
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.